

Michael S. Mega, MD, PhD
Director, Center for Cognitive Health
10200 SW Eastridge Street, Suite 105
Portland, Oregon 97225
Phone: 503-207-2066
Fax: 503-548-4981
Email: michael@centerforcognitivehealth.com

EDUCATION

Postgraduate

1994 UCLA School of Medicine, Los Angeles, CA
Research Fellow in Neurobehavior
1992 Boston University, Boston, MA
Resident, Clinical Neurology
1989 Georgetown University/VAMC, Washington, D.C.
Internship (Medicine)

Medical

1988 George Washington University, Washington, D.C.
Degree in Medicine

Graduate

2003 Ph.D. in Neuroscience, UCLA, Los Angeles, CA

Undergraduate

1984 University of California, Santa Barbara, CA
B.S. Physiological Psychology / B.A. Philosophy

RESEARCH EXPERIENCE

2008-present Investigation of a community-based sample of individuals with subjective cognitive decline for biomarkers of Alzheimer's disease.
2002 - 2008 Consultant in functional and structural neuroimaging research for Neural Net Research and the Laboratory of Neuro Imaging Department of Neurology, University of California, Los Angeles, CA.
1994-2002 Neuroimaging mapping of structure and function in health and disease.
Arthur W. Toga, PhD and John C. Mazziotta, MD PhD, Department of Neurology, University of California, Los Angeles, CA.
1992-2002 Investigation of human cognitive and behavioral abnormalities.
D. Frank Benson, MD and Jeffrey L. Cummings, MD Department of Neurology, University of California, Los Angeles, CA.
1991-1992 Lesion localization in language and cognitive disorders.
Michael P. Alexander, MD Department of Neurology, Boston University, Boston, MA.
1983-1984 Analysis of brain 5-HT Metabolites in tyrosine dietary deficient rats.
Loy Lytle, PhD, Department of Psychopharmacology, University of California, Santa Barbara, CA.

CLINICAL POSITIONS

2015-present	Director, Center for Cognitive Health, Portland OR.
2004-2015	Director, Cognitive Assessment Clinic, Brain Institute, Providence Health System, Portland OR.
2002-2003	Functional and Structural Imaging Investigator Pacific Health Research Institute, Honolulu, HI.
1999-2002	Director, Imaging sub-core Alzheimer's Disease Research Center, UCLA School of Medicine, Los Angeles, CA.
1997-2002	Assistant Professor in Neurology - UCLA School of Medicine, Los Angeles, CA.
1996-2002	Director, Memory Disorders and Alzheimer's Disease Clinic, UCLA School of Medicine, Los Angeles, CA.
1992-1997	Clinical Instructor in Neurology - UCLA School of Medicine, Los Angeles, CA.

MEDICAL LICENSURE

State of Massachusetts Medical Licensure
September 1990 (No. 73543), inactive

State of California Medical Licensure
September 1992-2006 (No. GO75911)

State of Oregon Medical Licensure
April 1993 (No. MD18185) retired

Board Certified, American Board of Psychiatry and Neurology
January 1997 (43527) renewed 2019.

AWARDS and HONORS

2005	Examiner, American Academy of Neurology Residency Exams
2001	Harold Brenner Pepinsky Early Career Award (Ohio State University)
1997-2002	NIA K08 Clinical Scientist Development Award
1994-1995	UCLA Alzheimer's Disease Center Research Grant
1994	Ralph Goldman Research Award
1983	Elected to write Honors Thesis in Philosophy by faculty

Clinical Trials

2025 PI, A randomized, placebo-controlled, parallel group, 72-week study to evaluate the efficacy and safety of VHB937 in participants with early Alzheimer's Disease followed by an Extension.

- 2025 PI, A Phase II, 26-week, Double-blind, Placebo-controlled Study to Assess the safety, Tolerability, Pharmacokinetics, and Efficacy of ONO-2020 in Patients with Mild to Moderate Alzheimer's Disease.
- 2025 PI, A Phase 2b/3, Double-Blind, Placebo-Controlled, Parallel-Group, 36-Week, 2-Arm Trial to Assess the safety, Tolerability, and Efficacy of Xanamem® 10 mg Daily in Patients with Mild or Moderate Dementia Due to Alzheimer's Disease.
- 2024 PI, Evaluation of the Lilly SP-X P-tau217 Assay by Measuring Changes in the Intended Patient Management between Pre- and Post-P-tau217 Result: A Randomized Clinical Utility Study
- 2023 PI, A Phase 3 Double-blind, Randomized, Placebo-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of AR1001 over 52 weeks in Participants with Early Alzheimer's Disease
- 2023 PI, A Phase 2b Clinical Study of the P28 Alpha Kinase Inhibitor Neflamapimod in Patients with Dementia with Lewy Bodies (DLB).
- 2023 PI, A Randomized, Double-blind, Sham-controlled, Adaptive-Design Pivotal Study of Sensory Stimulation in Subjects with Alzheimer's Disease (Hope Study).
- 2022 PI, Assessment of safety and efficacy measured by amyloid reduction of Remternetug in early symptomatic Alzheimer's disease
- 2022 PI, A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Study Evaluating the Safety and Efficacy of Simufilam 100 mg Tablets in Subjects with Mild-to-Moderate Alzheimer's Disease.
- 2022 PI, A Randomized, Placebo-Controlled, Double-Blind Study of ATH-1017 Treatment in Subjects with Parkinson Disease Dementia or Dementia with Lewy Bodies.
- 2022 PI, International Collaboration for Real-World Evidence in Alzheimer's Disease (ICARE AD)- A Prospective Real-World Observational Study of Aducanumab in Patients with Alzheimer's Disease in the US.
- 2022 PI, A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of AL002 in Participants with Early Alzheimer's Disease.
- 2022 PI, A study of donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease.
- 2022 PI, A randomized double-blind placebo-controlled clinical trial investigating the effect and safety of oral semaglutide in subjects with early Alzheimer's disease (EVOKE and EVOKE plus).
- 2021 PI, A Phase III Study of donanemab (LY3002813) in Participants with Early Alzheimer's Disease (TRAILBLAZER-ALZ 2).
- 2021 PI, A Randomized, Placebo-Controlled, Translational Study of ATH-1017 in Subjects with Mild to Moderate Alzheimer's Disease.
- 2021 PI, A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety and Biomarker Effects of ALZ-801 in Subjects with Early Alzheimer's Disease and APOE4/4 Genotype.
- 2020 PI, TauRx TRx-237-039 Phase III, Randomized, Double-Blind, Placebo-Controlled, Three-Arm, 12-Month, Safety and Efficacy Study of TRx0237 Monotherapy in Subjects with Alzheimer's Disease Followed by a 12-Month Open-Label Treatment.

- 2020 PI, 2020 PI, Phase III Eisai BAN2404-301 Treatment in AD/MCI A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study with an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects with Early Alzheimer's Disease.
- 2019 PI, vTv Therapeutics TTP488-305 Phase III Randomized, Double-blind, Placebo-controlled, Multicenter Studies to Evaluate the Safety and Efficacy of Azeliragon as a Treatment for Subjects with Mild Alzheimer's Disease and Impaired Glucose Tolerance.
- 2018 PI, Phase III Janssen ALZ2001 G-PACC Retest Study a cross-sectional, Multinational, Noninterventional Study to Evaluate the Psychometric Comparability of Culturally Adapted Versions of the Global Preclinical Alzheimer's Cognitive Composite (G-PACC).
- 2016 PI, Phase III Janssen ALZ2003 Treatment in Preclinical AD A Phase 2b/3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Study Investigating the Efficacy and Safety of JNJ-54861911 in Subjects Who Are Asymptomatic at Risk for Developing Alzheimer's Dementia.
- 2016 PI, Phase III Eisai E2609-302 Treatment in MCI A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study with an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects with Early Alzheimer's Disease.
- 2015 PI, Phase III Merck MK8931-019 Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 in Subjects with Amnesic Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal AD).
- 2015 PI, Phase III, Randomized, Double-Blind, Placebo Controlled, Multi-Center Registration Trial to Evaluate the Efficacy and Safety of TTP488 In Patients With Mild Alzheimer's Disease Receiving Acetylcholinesterase Inhibitors and/or Memantine.
- 2014 PI, Phase III A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 24-Week, Phase 2 Study of Two Doses of EVP-6124 Hydrochloride or Placebo in Subjects with Mild to Moderate Alzheimer's Disease.
- 2010 PI, Phase IIIb A 24 Week, Prospective, Randomized, Parallel-group, Double-blind, Multi-center Study (ENA713DUS44) Comparing the Effects of Rivastigmine Patch 15 cm² vs. Rivastigmine Patch 5 cm² on ACTivities of Daily Living and Cognition in Patients with Severe Dementia of the Alzheimer's Type.
- 2010 PI, Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effects of BMS-708163 in the Treatment of Patients with Prodromal Alzheimer's Disease.
- 2007 PI, Phase III Double-Blind, Long-Term Safety and Tolerability Trial of Bapineuzumab (AAB-001, ELN115727) In Subjects with Alzheimer Disease.
- 2007 PI, Phase IIIb 48-Week, Multicenter, Randomized, Double-Blind, Parallel-Group Evaluation of the Comparative Efficacy, Safety, and Tolerability of Exelon® 10 and 15 cm² Patch in Patients with Mild to Moderate Alzheimer's Disease (AD) Showing Functional and Cognitive Decline.
- 2003 PI, Phase IIIb FDG-PET effects from metrifonate treatment in AD.
- 2002 PI, Phase III FDG-PET Effects from Metrifonate Treatment in AD.

JOURNAL/GRANT REVIEWER

Biomarkers in Medicine

Neurology

NeuroImage

Lancet (Neurology)
NIH Study Section 1998
Alzheimer's Association
Oregon Partnership for Alzheimer's Research
American Foundation for Aging Research

SOCIETY MEMBERSHIPS

American Academy of Neurology
Behavioral Neurology Society
American Neuropsychiatric Association

ORIGINAL ARTICLES

1. Kline SA, **Mega MS**. Stress-Induced Neurodegeneration: The Potential for Coping as Neuroprotective Therapy. *Am J Alzheimers Dis Other Demen* 2020; 35 (1):1-13.
2. Dinov ID, Boscardin JW, **Mega MS**, Sowell EL, Toga AW. A Wavelet-Based Statistical Analysis of fMRI data: I. Motivation and Data Distribution Modeling. *Neuroinformatics* 2005;3(4):319-342.
3. **Mega MS**, Dinov ID, Mazziotta JC, Manese M, Thompson PM, Lindshield C, Moussai J, Tran N, Olsen K, Felix J, Zoumalan CI, Woods RP, Toga AW. Automated Brain Tissue Assessment in the Elderly and Demented Population: Construction and Validation of a Sub-Volume Probabilistic Brain Atlas. *NeuroImage* 2005; 26: 1009-1018.
4. **Mega MS**, Dinov ID, Porter V, Chow G, Reback E, Davoodi P, O'Connor SM, Carter MF, Felix J, Amezcua H, Cummings JL. Metabolic Patterns Associated with the Clinical Response to Galantamine Therapy: An FDG-PET Study. *Arch Neurol* 2005; 62: 721-728.
5. Senanarong, V, Cummings JL, Fairbanks L, **Mega MS**, Masterman M, O'Connor SM, Strickland TL. Agitation in Alzheimer's Disease Is a Manifestation of Frontal Lobe Dysfunction. *Dement Geriatr Cogn Disord* 2004; 17: 14-20.
6. Fuh J-L, **Mega MS**, Binetti G, Wang S-J, Magni E, Cummings JL. A transcultural study of agitation in dementia: environmental influences and associated behaviours. *J Geriatr Psychiat Neurol*. 2002; 15: 171-174.
7. **Mega MS**, Small GW, Xu ML, Felix J, Ercoli LM, Bookheimer SY, Toga AW. Hippocampal atrophy in persons with mild cognitive impairment. *Psychosomatic Medicine*. 2002; 64: 487-492.
8. Kumar A, Thomas A, Lavretsky H, Yue K, Huda A, Curran J, Venkatraman T, Estanol L, Mintz J, **Mega MS**, Toga A. Frontal white matter biochemical abnormalities in late-life

major depression detected with proton magnetic resonance spectroscopy. *Am J Psychiatry* 2002; 159: 630-636.

9. Dinov ID, **Mega MS**, Thompson PM, Woods RP, Sumners DWL, Sowell EL, Toga AW. Quantitative Comparison and Analysis of Image Registration Using Frequency-Adaptive Wavelet Shrinkage. *IEEE Trans. Information Technology in Biomedicine*. 2002; 6: 73-85.
10. **Mega MS**. Differential diagnosis of dementia: clinical examination and laboratory assessment. *Clin Cornerstone*. 2001; 3: 1-14.
11. Toga AW, Thompson PM, **Mega MS**, Narr, KL, Blanton RE. Probabilistic approaches for atlasing normal and disease-specific brain variability. *Anatomy and Embryology*. 2001; 204: 267-282.
12. **Mega MS**. The entorhinal cortex in Alzheimer's disease. *J Neurol Neurosurg Psychiatry*. 2001; 71: 431-432
13. Fuh J-L, Liu C-K, **Mega MS**, Wang S-J, Cummings JL. Behavioral disorders and caregivers' reaction in Taiwanese patients with Alzheimer's disease. *International Psychogeriatrics* 2001; 13: 121-128.
14. Hirono N, **Mega MS**, Dinov ID, Mishkin F, Cummings JL. Neuroimaging correlates of aggressive behavior in dementia patients. *Research and Practice In Alzheimer's Disease*. 2001; 5: 27-32.
15. Tekin S, **Mega MS**, Masterman MD, Chow T, Vinters H, Cummings JL. Orbitofrontal and anterior cingulate NFT burden is associated with agitation in Alzheimer's disease. *Ann Neurol* 2001; 49(3):355-361.
16. Paulsen JS, Ready RE, Hamilton JM, **Mega MS**, Cummings JL. Neuropsychiatric aspects of Huntington's disease. *J Neurol Neurosurg Psychiatry*. 2001; 71: 310-314.
17. **Mega MS**, Cummings JL, Dinov ID, Felix J, O'Connor SM, Reback EM, Masterman MD, Phelps ME, Small GW, Toga AW. Cognitive and metabolic responses to metrifonate therapy in Alzheimer's disease. *Neuropsychiatry Neuropsychol Behav Neurol* 2001; 14(1):63-68.
18. Thompson PM, **Mega MS**, Woods RP, Zoumalan CI, Lindshield CJ, Blanton RE, Moussai J, Holmes CJ, Cummings JL, Toga AW. Cortical change in Alzheimer's disease detected with a disease-specific population-based brain atlas. *Cerebral Cortex* 2001; 11(1):1-16.
19. Thompson PM, **Mega MS**, Toga AW. Disease-specific probabilistic brain atlases. *IEEE Proc. of the International Conference on Computer Vision and Pattern Recognition, and Workshop on Mathematical Methods in Biomedical Image Analysis*. 2000, 237-234.

20. Small GW, Ercoli LM, Silverman DHS, Huang S-C, Komo S, Bookheimer SY, Lavretsky H, Miller K, Siddarth P, Rasgon NL, Mazziotta JC, Saxena S, Wu HM, **Mega MS**, Cummings JL, Saunders AM, Pericak-Vance MA, Roses AD, Barrio JR, Phelps ME. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. *PNAS* 2000; 97(11): 6037-6042.
21. Hirono N, **Mega MS**, Dinov ID, Mishkin F, Cummings JL. Left frontotemporal hypoperfusion is associated with aggression in patients with dementia. *Arch Neurol* 2000; 57:861-866.
22. **Mega MS**, Dinov ID, Lee L, O'Connor SM, Masterman DM, Wilen B, Mishkin FS, Toga AW, Cummings JL. Orbital and dorsolateral frontal perfusion defects associated with behavioral response to cholinesterase inhibitor therapy in Alzheimer's disease. *J Neuropsychiatry Clin Neurosci* 2000; 12:209-218.
23. **Mega MS**, Lee L, Dinov ID, Mishkin F, Toga AW, Cummings JL. Cerebral correlates of psychotic symptoms in Alzheimer's disease. *J Neurol Neurosurg Psychiatry* 2000; 69:167-171.
24. **Mega, MS**. The cholinergic deficit in Alzheimer's disease: impact on cognition, behaviour and function. *The International Journal of Neuropsychopharmacology* 2000; 3:3-12.
25. Dinov ID, **Mega MS**, Thompson PM, Lee L, Woods RP, Holmes CJ, Sumners DWL, Toga AW. Analyzing functional brain images in a probabilistic atlas: A validation of sub-volume thresholding. *J Comp Asst Tomo* 2000; 24(1):128-138.
26. Thompson PM, Woods RP, **Mega MS**, Toga AW. Mathematical/Computational Challenges in Creating Deformable and Probabilistic Atlases of the Human Brain. *Human Brain Mapping* 2000; 9:81-92.
27. **Mega MS**, Masterman DM, O'Connor SM, Barclay TR, Burzynski MJ, Cummings JL. The spectrum of behavioral responses with cholinesterase inhibitor therapy in Alzheimer's disease. *Arch Neurol* 1999; 56:1388-1393.
28. **Mega MS**, Chu T, Mazziotta JC, Trivedi KH, Thompson PM, Shah AK, Aron J, Frautschy SA, Cole G, Toga AW. Mapping biochemistry to metabolism: FDG-PET and amyloid burden in Alzheimer's disease. *NeuroReport* 1999; 10:2911-2917.
29. **Mega MS**. D. Frank Benson's quest for a better view: The neuroimaging of neurobehavior. *Aphasiology* 1999; 13(1):41-53.
30. Litvan I, Cummings JL, **Mega MS**. Neuropsychiatric features of corticobasal degeneration. *J Neurol Neurosurg Psychiatry* 1998; 65:717-721.
31. Litvan I, Paulsen JS, **Mega MS**, Cummings JL. Neuropsychiatric assessment of patients with hyperkinetic and hypokinetic movement disorders. *Arch Neurol* 1998; 55:1313-1319.

32. Thompson PM, Moussai J, Zohoori S, Goldkorn A, Khan AA, **Mega MS**, Small GW, Cummings JL, Toga AW. Cortical variability and asymmetry in normal aging and Alzheimer's disease. *Cerebral Cortex* 1998; 8:492-509.
33. Binetti G, **Mega MS**, Magni E, Padovani A, Rozzini L, Bianchetti A, Trabucchi M, Cummings JL. Behavioral disorders in Alzheimer disease: a transcultural perspective. *Arch Neurol* 1998; 55:539-544.
34. **Mega MS**, Thompson PM, Cummings JL, Back CL, Xu LQ, Zohoori S, Goldkorn A, Moussai J, Fairbanks L, Small GW, Toga AW. Sulcal variability in the Alzheimer's brain: correlations with cognition. *Neurology* 1998; 50:145-151.
35. **Mega MS**, Cohenour R. Akinetic mutism: disconnection of frontal-subcortical circuits. *Neurology, Neuropsychology, and Behavioral Neurology* 1997; 10:254-259.
36. Thompson PM, MacDonald D, **Mega MS**, Holmes CJ, Evans AC, Toga AW. Detection and mapping of abnormal brain structure with a probabilistic atlas of cortical surfaces. *J Comp Asst Tomogr* 1997; 21:567-581.
37. **Mega MS**, Cummings JL, Salloway S, Malloy P. The limbic system: an anatomic, phylogenetic, and clinical perspective. *Neuropsychiatry Clin Neurosci* 1997; 9:315-330.
38. **Mega MS**, Chen SS, Thompson PM, Woods RP, Karaca TJ, Tiwari A, Vinters HV, Small GW, Toga AW. Mapping histology to metabolism: coregistration of stained whole brain sections to premortem PET using 3D cryomacrotome reconstruction as a reference. *NeuroImage* 1997; 5:147-153.
39. Cummings JL, **Mega MS**. Alzheimer's disease: Pathophysiology and treatment. *ConsultPharm* 1996; 11 (suppl E):8-15.
40. Yang J, Huang SC, **Mega MS**, Lin KP, Toga AW, Small GW, Phelps ME. Investigation of partial volume correction methods for brain FDG-PET studies. *IEEE Transactions on Nuclear Science* 1996; 43:3322-3327.
41. **Mega MS**, Masterman DL, Benson DF, Vinters HV, Tomiyasu U, Craig AH, Foti DJ, Kaufer DI, Scharre DW, Fairbanks LA, Cummings JL. Dementia with Lewy bodies: reliability and validity of clinical and pathologic criteria. *Neurology* 1996; 47:1403-1409.
42. Litvan I, **Mega MS**, Cummings JL, Fairbanks L. Neuropsychiatric aspects of progressive supranuclear palsy. *Neurology* 1996; 47:1184-1189.
43. **Mega MS**, Cummings JL, Fiorello T, Gornbein J. The spectrum of behavioral changes in Alzheimer's disease. *Neurology* 1995; 46:130-135.

44. Geschwind DH, Iacononi M, **Mega MS**, Zaidel DW, Cloughesy T, Zaidel E. The alien hand syndrome: interhemispheric motor disconnection due to a lesion in the midbody of the corpus callosum. *Neurology* 1995; 45:802-808.
45. Cummings JL, **Mega MS**, Grey K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. *Neurology* 1994; 44:2308-2314.
46. **Mega MS**, Cummings JL. Frontal subcortical circuits and neuropsychiatric disorders. *J Neuropsychiatry Clin Neurosci* 1994; 6:358-370.
47. **Mega MS**, Alexander MP. Subcortical aphasia: the core profile of capsulostriatal infarcts. *Neurology* 1994; 44:1824-1829.

BOOKS

1. Cummings JL, **Mega MS**. Neuropsychiatry and Behavioral Neuroscience. Oxford Press, New York; 2003.

BOOK CHAPTERS

1. **Mega MS**. Akinetic Mutism. In: Kreutzer J., DeLuca J., Caplan B. (eds) Encyclopedia of Clinical Neuropsychology. Springer, Cham 2017.
2. **Mega MS**. Cingulate Gyrus. In: Kreutzer J., DeLuca J., Caplan B. (eds) Encyclopedia of Clinical Neuropsychology. Springer, Cham 2017.
3. Toga AW, **Mega MS**, Thompson PM. Neuroimaging Alzheimer's disease. In: Esiri, MM, Lee VM-Y, Trojanowski JQ eds. The Neuropathology of Dementia 2nd edition. Cambridge University Press, Cambridge; 128-160, 2004.
4. **Mega MS**. Memory Disorders. In: D'Esposito, M, ed. Neurological Foundations of Cognitive Neuroscience. MIT Press, Boston; 41-66, 2003.
5. **Mega MS**. Neuroimaging in Dementia: now and in the future. in American Academy of Neurology Syllabus for the annual meeting, 2002: Denver CO.
6. Thompson PM, **Mega MS**, Vidal C, Rapoport JL, Toga AW. Detecting disease-specific patterns of brain structure using cortical pattern matching and a population-based probabilistic brain atlas. IEEE Conference on Information Processing in Medical Imaging, Davis, CA. In: Lecture notes in computer science 2082 (Insana M, Leahy R, eds), Springer, New York: 488–501, 2001.

7. **Mega MS.** The Orbitofrontal Cortex: Connectional Neuroanatomy. In: Bellodi L, & Cavallaro R, eds. The Basal-Cortical Function In Obsessive Compulsive Disorder Spectrum. Pacini Editore, Pisa; 19-35, 2000.
8. **Mega MS, Cummings JL.** Frontal-subcortical circuits: anatomy and function. In: Salloway S, ed. Neuropsychiatry and the Basal Ganglia. Oxford Univ. Press; 15-32, 2000
9. Thompson PM, **Mega MS**, Narr KL, Sowell ER, Blanton RE, Toga AW. Brain Image Analysis and Atlas Construction. In: Fitzpatrick M, ed. SPIE Handbook on Medical Image Analysis. Society of Photo-Optical Instrumentation and Engineers (SPIE) Press; 4-76, 2000.
10. Thompson PM, **Mega MS**, Toga AW. Disease-specific brain atlases. In: Mazziotta JC, Toga AW, Frackowiak R, eds. Brain Mapping: The Disorders. San Diego: Academic Press; 131-177, 2000.
11. **Mega MS**, Thompson PM, Toga AW, Cummings JL. Neuroimaging in Dementia. In: Mazziotta JC, Toga AW, Frackowiak R, eds. Brain Mapping: The Disorders. San Diego: Academic Press; 217-293, 2000.
12. **Mega MS**, Alexander MP, Cummings JL, Benson DF. The Aphasias. In: Joynt, RJ, ed. Baker's Clinical Neurology. Philadelphia: Lippincott.
13. **Mega MS.** Neuropsychiatry in Dementia. in American Academy of Neurology Syllabus for the annual meeting, 1999: Toronto Canada.
14. **Mega MS**, Cummings JL, Salloway S, Malloy P. The limbic system: an anatomic, phylogenetic, and clinical perspective. In: Salloway S, Malloy P, Cummings JL, eds. The Neuropsychiatry of Limbic and Subcortical Disorders. Washington, DC: American Psychiatric Press, Inc., 1997.
15. **Mega MS**, Cummings JL. The cingulate and cingulate syndromes. In: Cummings JL, Trimble MR, ed. Contemporary Behavioral Neurology. Boston: Butterworth Heinemann, 1996.
16. **Mega MS**, Cummings JL. Dementia. in Psychiatric Care in the Nursing Home, Reichman WE, ed. Oxford Univ. Press 1996.
17. Cummings JL, **Mega MS**. Anatomy of frontal-subcortical circuits. in American Academy of Neurology Syllabus for the annual meeting, 1995: Seattle WA.
18. **Mega MS**, Ween JE, Albert ML. Higher visual functions. in Current Neuro-ophthalmology, Lessell S and Van Dalen J, eds. Vol. 3, St. Louis: Mosby, 1991.

ABSTRACTS

1. **Mega MS**, Dinov ID, Mazziotta JC, Manese M, Thompson PM, Lindshield C, Moussai J, Tran N, Olsen K, Felix J, Zoumalan CI, Woods RP, Toga AW. Automated Brain Tissue Assessment in the Elderly and Demented Population: Construction and Validation of a Sub-Volume Probabilistic Brain Atlas. *The 9th International Conference on Alzheimer's Disease and Related Disorders* 2004 Philadelphia.
2. **Mega MS**, Dinov ID, Porter V, Chow G, Reback E, Davoodi P, O'Connor SM, Carter MF, Felix J, Amezcua H, Cummings JL, Toga AW. Metabolic Patterns Associated with the Clinical Response to Galantamine Therapy: An FDG-PET Study. *The 9th International Conference on Alzheimer's Disease and Related Disorders* 2004 Philadelphia.
3. **Mega MS**, Dinov ID, Porter V, Chow G, Reback E, Davoodi P, O'Connor SM, Carter MF, Felix J, Amezcua H, Cummings JL, Toga AW. Metabolic Patterns Associated with the Clinical Response to Galantamine Therapy: An FDG-PET Study. *Neurology* 2004; 59.
4. **Mega MS**, Dinov ID. Functional imaging assessment of cholinesterase inhibitor therapy in Alzheimer's disease: HMPAO-SPECT and FDG-PET within a probabilistic atlas. *The AAGP* 2003 Toronto, Canada.
5. **Mega MS**, Dinov ID. Neuroimaging in Vascular Dementia. *The Vascular Dementia Conference* 2003 Prague, Czech Republic.
6. **Mega MS**, Dinov ID, Dailey J, Manese MP, Felix J, Tran NP, Toga AW, Cummings JC. Functional imaging assessment of cholinesterase inhibitor therapy in Alzheimer's disease: HMPAO-SPECT and FDG-PET within a probabilistic atlas. *The 8th International Conference on Alzheimer's Disease and Related Disorders* 2002 Stockholm, Sweden.
7. **Mega MS**, Tran NP, Dailey J, Dinov ID, Thompson PM, Felix J, Toga AW. The hippocampus in aging and dementia: Quantitative, linear, volumetric & 3D morphological mapping using a probabilistic Alzheimer's brain atlas. *The 8th International Conference on Alzheimer's Disease and Related Disorders* 2002 Stockholm, Sweden.
8. **Mega MS**, Manese MP, Felix J, et al. Anterior cingulate activation occurs across cholinesterase inhibitor therapy in Alzheimer's disease. *Int Psychogeriatr* 2001; 13(suppl 2):OS 6-2.
9. Dinov ID, **Mega MS** & Toga AW. Wavelet Analysis of Image Registration, *Abstracts of Papers Presented to the American Mathematical Society* 2001; Vol. 21(3): 956-974.
10. Thompson PM, Zubicaray G, Janke AL, Rose SE, **Mega MS**, Semple J, Hong MS, Cummings JL, DODDRELL DM, Toga AW. Detecting Dynamic (4D) Profiles of Degenerative Rates in Alzheimer's Disease Patients, Using High-Resolution Tensor Mapping and a Brain Atlas Encoding Atrophic Rates in a Population. *Neurology* 2001; 56:A264

11. Dinov ID , **Mega MS**, Manese M, Felix J, Tran N, Lindshield C, Cummings JL, Toga AW. Construction of the First Rest-State Functional Sub-Volume Probabilistic Atlas of Normal Variability in the Elderly and Demented Brain. *Neurology* 2001; 56:A248
12. Manese M , **Mega MS**, Tran N, Felix J, Cummings JL, Toga AW. Linear Measures of Temporal Lobe Regions in Aging and Dementia: Reliability and Validity Based upon High Resolution Hippocampal Volumetry. *Neurology* 2001; 56:A263
13. Crabtree EC, **Mega MS**, Linshield CJ, Dinov ID, Thompson PM, Felix J, Fennema CN, Archibald SL, Jernigan TL, Cummings JL, Toga AW. Alzheimer grey matter loss across time: unbiased assessment using a probabilistic Alzheimer brain atlas. *Soc for Neurosci Abs* 2000, 26:294.
14. Thompson PM, **Mega MS**, Cummings JL, Toga AW. Detecting dynamic (4D) profiles of degenerative rates in Alzheimer's disease patients, using tensor mapping and a population-based brain atlas. *Soc for Neurosci Abs* 2000, 26:294.
15. Tekin S, **Mega MS**, Masterman DM, Chow T, Garakian J, Vinters H, Cummings JL. Orbital frontal and anterior cingulate cortex neurofibrillary tangle burden is associated with agitation in Alzheimer's disease. *Ann Neurology* 2000; 48(3):461.
16. **Mega MS**, Thompson PM, Cummings JL, Toga AW. The UCLA Alzheimer's disease atlas project: Structural and functional applications. *Ann Neurology* 2000; 48(3):427.
17. **Mega MS**, Cummings JL, Masterman DM, Dinov ID, Felix J, O'Connor SM, Toga AW. Metabolic responses to donepezil therapy in Alzheimer's disease. *Neurology* 2000; 54:A416.
18. Thompson PM, **Mega MS**, Woods RP, Zoumalan CL, Lindshield CJ, Blanton RE, Moussai J, Holmes CJ, Dinov ID, Cummings JL, Toga AW. Early cortical change in Alzheimer's disease detected with disease-specific, population-based, probabilistic brain atlas. *Neurology* 2000; 54:A475.
19. **Mega MS**, Lindshield C, Leung M, Dinov ID, Thompson PM, Felix J, Fennema CN, Archibald SL, Jernigan TL, Toga AW. Application of a sub-volume probabilistic human brain atlas for the elderly and demented populations: Automated mapping of regional grey matter loss. *NeuroImage* 2000; 11(5):S178
20. **Mega MS**, Fennema CN, Dinov ID, Thompson PM, Archibald SL, Lindshield C, Felix J, Toga AW, Jernigan TL. Construction, testing, and validation of a sub-volume probabilistic human brain atlas for the elderly and demented populations *NeuroImage* 2000; 11(5): S597
21. Small GS, Ercoli LM, Huang SC, Komo S, Bookheimer SY, Saxena S, Silverman DH, **Mega MS**, Mazziotta JC, Wu HM, Cummings JL, Phelps ME. PET and genetic risk for Alzheimer's disease. *J Nuclear Medicine* 1999; 40(5): 70P.

22. **Mega MS**, Thompson PM, Woods RP, Dinov ID, Zoumalan CI, Cummings JL, Mazziotta JC, Collins RC, Toga AW. Functional imaging analysis within an Alzheimer's disease atlas: cortical variability maps of anatomic and PET registration errors. *Soc for Neurosci Abs* 1999, 25:14.
23. Thompson PM, **Mega MS**, Woods RP, Blanton RE, Moussai J, Zoumalan CI, Cummings JL, MacDonald D, Evans AC, Toga AW. (1999). Detecting 3D patterns of Alzheimer's disease pathology with a disease-specific, population-based probabilistic brain atlas. *Soc for Neurosci Abs* 1999, 25:1801
24. Thompson PM, **Mega MS**, Woods RP, Blanton RE, Moussai J, Zoumalan CI, Aron J, Cummings JL, Toga AW. A probabilistic atlas of the human brain in Alzheimer's disease emerging patterns of variability, asymmetry and degeneration. *NeuroImage* 1999; 9(6):S597
25. Holmes CJ, **Mega MS**, Toga AW. An Elderly Target for Automatic MRI Registration. *NeuroImage* 1999; 9(6):S185
26. **Mega MS**, Dinov ID, Lindshield CJ, Thompson PM, Toga AW. Differences between raw and partial volume corrected analyses of PET data using sub-volume thresholding in a probabilistic ROI atlas. *NeuroImage* 1999; 9(6):S184
27. Dinov ID, Woods RP, Thompson PM, Summers DW L, **Mega MS**, Sowell ER, Toga AW. Quantitative comparison and analysis of stereotactic image registration wavelet based frequency adaptive warp ranking. *NeuroImage* 1999; 9(6):S141
28. Lindshield CJ, **Mega MS**, Narr KL, Moussai J, Dinov ID, Sowell ER, Thompson PM, Woods RP, Sharma T, Toga AW. Age related frontal grey matter loss: volumetric tissue analysis in a probabilistic atlas using high order nonlinear registration. *NeuroImage* 1999; 9(6):S102.
29. Felix J, **Mega MS**, Dinov ID, Toga AW, Cummings JL. Perfusion defects in the parietal cortex and dorsolateral caudate bilaterally are associated with depressed mood in Alzheimer's disease patients: A ^{99m}Tc -HMPAO SPECT analysis. *NeuroImage* 1999; 9(6):S670.
30. **Mega MS**, Felix J, Dinov ID, McPherson SM, Cummings JL, Toga AW. Anterior cingulate and frontal polar hypoperfusion is associated with declines in verbal fluency in older persons with mild cognitive impairment: A ^{99m}Tc -HMPAO SPECT study. *NeuroImage* 1999; 9(6):S350.
31. Shah AK, **Mega MS**, Trivedi KH, Lindshield CJ, Duhaylongsod LM, Dooley JR, Thompson PM, Sterling L, Yu J, Leung M, Saedi G, Zoumalan CI, Nguyen A, Toga AW. A population based digital atlas of the Alzheimer's brain integrating functional, histological, and biochemical data. *NeuroImage* 1999; 9(6):S586.

32. Sanchez MC, **Mega MS**, Trivedi KH, Shah AK, Sterling L, Yu J, Leung M, Toga AW. Microscopic assessment of a 3-dimensional brain volume. *NeuroImage* 1999; 9(6):S585
33. Kwong EM, **Mega MS**, Thompson PM, Xu ML, Ercoli LM, Cummings JL, Small GS, Felix J, Toga AW. Three dimensional hippocampal maps in normal aging, older persons with mild cognitive impairment and patients with Alzheimer's disease. *Neurology* 1999; 52:A570-A571.
34. Zoumalan CI, **Mega MS**, Thompson PM, Grigoriadis A, Nguyen A, Toga AW. Three-dimensional sulcal deformations of the brain in aging and dementia are related to cognitive performance. *NeuroImage* 1999; 9(6):S602.
35. Zoumalan CI, **Mega MS**, Thompson PM, Fuh J-L, Lindshield C, Toga AW. Mapping 3D cortical variability in normal aging and Alzheimer's disease. *Neurology* 1999; 52:A369.
36. Dinov ID, **Mega MS**, Lee L, Willen B, Mishkin F, Toga AW. The effects of education on brain perfusion in Alzheimer's disease. *Neurology* 1999; 52:A367.
37. Thompson PM, **Mega MS**, Woods RP, Blanton RE, Moussai J, Zoumalan CI, Dinov ID, Cummings JC, MacDonald D, Evans AC, Toga AW. Detecting 3D patterns of Alzheimer's disease pathology with a probabilistic brain atlas based on continuum mechanics. *Neurology* 1999; 52:A570-571.
38. **Mega MS**, Cummings JL, Dinov ID, Masterman DM, Felix J, O'Connor SM, Reback ER, Toga AW. Metrifonate clinical benefits are correlated with activation of specific neuronal networks. *Neurology* 1999; 52:S14.
39. Woods RP, **Mega MS**, Thompson PM. Use of automated polynomial warping to create a magnetic resonance imaging atlas specific for the study of Alzheimer's disease. *Annals of Neurology* 1998; 44(3):449.
40. Dinov ID, Thompson PM, Woods RP, **Mega MS**, Holmes CJ, Sumners D, Toga AW. On permissibility of covariogram models with applications to analyzing human brain functional data. Conference on Statistical Analysis in Alzheimer's Disease Research, May 15-17 1998, Lexington, KY.
41. Blanton RE, Levitt JG, Thompson PM, Sowell ER, Narr KL, **Mega MS**, Sharma T, Collins RC, Toga AW. Normal developmental and aging effects on corpus callosum morphology. *Soc for Neurosci Abs* 1998; 24:999.
42. **Mega MS**, Woods RP, Thompson PM, Dinov ID, Lee L, Aron J, Zoumalan CI, Cummings JL, Toga AW. Detecting metabolic patterns associated with minimal cognitive impairment using FDG-PET analysis within a probabilistic brain atlas based upon continuum mechanics. *Soc for Neurosci Abs* 1998; 24:1269.

43. **Mega MS**, O'Connor SM, Lee L, Dinov ID, Cummings JL, Toga AW. Orbital frontal and anterior cingulate pretreatment perfusion defects on ^{99m}Tc -HMPAO -SPECT are associated with behavioral response to cholinesterase inhibitor therapy in Alzheimer's disease. *Neurology* 1998; 50:A250.
44. **Mega MS**, Aron J, Thompson PM, Lee L, Mogy J, Toga AW. Cortical surface variability of the Alzheimer's brain: correlates with cognition. *NeuroImage* 1998; 7(4):S523.
45. **Mega MS**, Trivedi KH, Mazziotta JC, Woods RP, Thompson PM, Lim J, Shah AK, Lindshield CJ, Sterling L, Wu J, Zoumalan CI, Toga AW. A population based multimodality atlas of the Alzheimer's brain: integrating pathology and metabolism. *NeuroImage* 1998; 7(4):S522.
46. Lee L, **Mega MS**, Dinov ID, Cummings JL, Toga AW. Dorsolateral frontal and Anterior Cingulate perfusion Defects on ^{99m}Tc -HMPAO -SPECT are associated with delusional behavior in Alzheimer's disease. *Neurology* 1998; 50:A362.
47. Thompson PM, **Mega MS**, Blanton RE, Moussai J, Zohoori S, Goldkorn A, Holmes CJ, MacDonald D, Small G, Cummings J, Toga AW. 3-Dimensional patterns of abnormal brain structure, anatomic variation and asymmetry in Alzheimer's disease. *The Journal of Neuropsychiatry and Clinical Neurosciences* 1997; 9:705.
48. **Mega MS**, Dinov ID, Lee L, Woods RP, Thompson PM, Holmes CJ, Back CL, Collins DL, Evans AC, Toga AW. Dissecting Neural Networks Underlying the Retrieval Deficit from the Amnesic Memory Disorder by Using ^{99m}Tc -HMPAO-SPECT. *The Journal of Neuropsychiatry and Clinical Neurosciences* 1997; 9:704.
49. Betz BP, **Mega MS**. Assessment of cognitive decline in patients with probable Alzheimer's disease. *The Journal of Neuropsychiatry and Clinical Neurosciences* 1997; 9:677.
50. Paulsen JS, **Mega MS**, Cummings JL. The spectrum of behavioral changes in Huntington's disease. *The Journal of Neuropsychiatry and Clinical Neurosciences* 1997; 9:655.
51. Fuh J-L, **Mega MS**, Thompson PM, Cummings JL, Toga AW. Cortical complexity maps and cognition in Alzheimer's disease. *The Journal of Neuropsychiatry and Clinical Neurosciences* 1997; 9:692.
52. Thompson PM, **Mega MS**, Blanton RE, Moussai J, Khan AA, Zohoori S, Mogy J, Aron J, Goldkorn A, Holmes CJ, Small GW, Cummings JL, MacDonald D, Evans AC, Collins RC, Toga AW. A detection system for mapping abnormal structure, anatomic variability, and brain asymmetry in Alzheimer's disease and aging, with 3D deformable probabilistic brain atlases. *Soc for Neurosci Abs* 1997; 23(2):2173.
53. Blanton RE, Thompson PM, Cannestra AF, **Mega MS**, Sharma MS, Levitt JL, McCracken JT, Toga AW. The relevance of Talairach stereotaxic space: A developmental study. *Soc for Neurosci Abs* 1997; 23(2):1309.

54. Wang AY, **Mega MS**, Pourrabbani S, Vinters HV, Cummings JL. Limbic and neocortical subgroups in Alzheimer's disease with Lewy bodies based on Braak and Braak plaque staging. *Soc for Neurosci Abs* 1997; 23(2):1648.
55. **Mega MS**, Small GW, Xu ML, Kim RS, Toga AW. Family history of dementia and apolipoprotein E ϵ 4 allele reverses normal hippocampal asymmetry. *Soc for Neurosci Abs* 1997; 23(2):2216.
56. Litvan I, Cummings J, **Mega M**. Neuropsychiatric features of corticobasal degeneration. *Annals of Neurology* 1997; 42(3):395.
57. Wang AY, **Mega MS**, Pourrabbani S, Cheng Y, Brooks AJ, Vinters HV, Cummings JL. Divergent Lewy body burden in limbic versus neocortex across Alzheimer disease severity stages. *Annals of Neurology* 1997; 42(3):402.
58. **Mega MS**, Chu T, Thompson P, Mazziotta J, Burt J, Aron J, Ghasri P, Chen S, Lim J, Cole GM, Toga AW. FDG-PET corrected with synaptophysin density is inversely related to A β burden in Alzheimer disease. *Annals of Neurology* 1997; 42(3):398.
59. Thompson PM, MacDonald D, **Mega MS**, Holmes CJ, Evans AC, Toga AW. Quantifying and Correcting for Variable Cortical Morphology in Functional Imaging using a Deformable Probabilistic Brain Atlas. *NeuroImage* 1997; 5(4):S423.
60. **Mega MS**, Chu T, Thompson P, Mazziotta JC, Cole G, Toga AW. Amyloid β protein density and cortical metabolism on FDG-PET in Alzheimer's Disease. *NeuroImage* 1997; 5(4):S346.
61. Tom TW, Wang AY, **Mega MS**, Tomiyasu U, Vinters HV, Masterman DL, Cummings JL. The relationship between Lewy bodies, neurofibrillary tangles, and senile plaques in hippocampi from patients with dementing disorders. *Neurology* 1997; 48: A141.
62. **Mega MS**, Chen SS, Tiwari A, Karaca TJ, Vinters HV, Thompson PM, Toga AW. Mapping pathology to metabolism: coregistration of stained whole brain sections to PET. *Neurosci Abs* 1996; 22: 1105.
63. Wang AY, **Mega MS**, Tomiyasu U, Vinters HV, Nakanishi AW, Cummings JL. Dopaminergic loss correlates with hippocampal Lewy body density. *Neurosci Abs* 1996; 22: 211.
64. Thompson PM, **Mega MS**, Moussai J, Zohoori S, Xu LQ, Goldkorn A, Khan AA, Coryell J, Small G, Cummings J, Toga AW. 3D probabilistic atlas and average surface representation of the Alzheimer's brain, with local variability and probability maps of ventricles and deep cortex. *Neurosci Abs* 1996; 22: 1105.

65. **Mega MS**, Xu LQ, Karaca TJ, Altshuler LL, Payne BA, Cohen MS, Small GW, Cummings JL, Toga AW. Standardization of MRI Volumetric Studies: Hippocampal atrophy predates clinical symptoms in individuals at risk for Alzheimer's disease. *Neurology* 1996; 46: A133.
66. **Mega MS**, Karaca TJ, Adamson CF, Schluender S, Pouratain N, Toga AW. Premortem - postmortem neuroimaging: a study of brain morphologic changes in man with MRI and cryomacrotome imaging. *Neurosci Abs* 1995; 21: 154.
67. **Mega MS**. Alzheimer's disease: etiology, prevention, and treatment efficacy. *Hawaii Medical Journal* 1995; 54: 719.
68. **Mega MS**. Treatment options in the acute stroke patient. *Hawaii Medical Journal* 1995; 54: 718.
69. Yang L, **Mega MS**, Lin KP, Huang SC, Toga A, Small G, Phelps ME. Validation of a combined neural network ART2 and statistical map method for brain MRI segmentation. Presentation at the annual meeting of The Society of Nuclear Medicine; 1995: Minneapolis, MN.
70. **Mega MS**, Masterman D, Vinters H, Tomiyasu U, Nam P, Scharre D, Craig AH, Foti D, Benson DF. Diffuse Lewy body disease: a clinical-pathologic study. *Neurology* 1995; 45(suppl 4): A240.
71. Toga AW, Ambach KL, **Mega MS**, Schluender S. Morphometric variability in 3D high resolution digital postmortem anatomy and *in vivo* MRI. *Neurosci Abs* 1994; 20: 04.
72. **Mega MS**, Cummings JL. Behavioral changes in Alzheimer's disease. *Neurology* 1994; 44:A240.
73. **Mega MS**, Alexander MP. Subcortical aphasia: the core profile of left lenticulostriate infarction. *Neurology* 1993; 43:A404.